Morgan (Thompson) Vazquez
Head of Recruitment Blueprint Medicines
Morgan Vazquez is Head of US Recruitment at Blueprint Medicines, where she leads talent acquisition across the organisation’s growing US footprint. With deep experience spanning biopharma and life sciences search, Morgan is passionate about building people-first cultures that enable teams to do their best work in pursuit of better outcomes for patients.
Seminars
- How can mid‑sized life sciences organizations sustain engagement and operational stability during a prolonged acquisition and six‑month talent‑at‑risk period?
- Learn how Blueprint Medicines implemented a practical talent cross‑pollination and contingency planning approach, redeploying internal capability, redistributing work, and partnering closely with HRBPs to reduce reliance on external hiring
- Discover how this strategy protected critical roles, supported meaningful stay conversations, and enabled employees to remain engaged and productive through uncertainty, offering a repeatable model for organizations navigating M&A or commercial scale‑up
This interactive Q&A examines the full arc of talent risk during acquisition, from the moment a deal is announced to the point of genuine integration stability. Drawing on both the crosspollination approach to talent-at-risk management and the pre-and post-close intervention framework, participants will examine what HR must do, and when, to prevent the quiet erosion of innovation capability that so often follows a deal.
- At what point in the M&A process does HR intervention have the greatest impact on talent retention?
- How do you identify which individuals and capabilities are truly critical, versus simply perceived as critical?
- What does a genuinely effective retention strategy look like for a population that has every reason to leave?
- How do you sustain innovation culture and engagement when the people driving it are uncertain about their future?
